Private equity giant Blackstone acquired a majority stake in Precision Medicine Group in a multi-billion-dollar transaction that valued the healthcare services and precision medicine platform at approximately $2.3 billion (including debt refinancing). The strategic buyout was structured to accelerate the growth of Precision Medicine Group's specialized oncology, biomarker, and clinical trial laboratory services.